Eribulin

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Adverse-effects 4 Mechanism-of-action 5 More General Terms 6 References

Indications

• FDA-approved for treatment of metastatic breast cancer, intended for patients who have already received at least two regimens of chemotherapy for late-stage disease

Dosage

• injection

Adverse-effects

• neutropenia
• fatigue
• nausea
• hair loss
• anemia
• neuropathy

Mechanism-of-action

• a microtubule inhibitor that limits growth of cancer cells

More General Terms

• antineoplastic agent (chemotherapeutic agent)

References

- FDA News Release: Nov. 15, 2010 FDA approves new treatment option for late-stage breast cancer [1] eribulin mesylate (Halaven)